Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention
I Gorczyca, A Michalska, M Chrapek… - Cardiology …, 2021 - journals.viamedica.pl
Background: Oral anticoagulants (OAC) are recommended in all patients with atrial
fibrillation (AF) after thromboembolic events without contraindications. It is hypothesized …
fibrillation (AF) after thromboembolic events without contraindications. It is hypothesized …
[HTML][HTML] A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: a comparison of efficacy and safety following treatment with …
Abstract Background Direct oral anticoagulants (DOACs) are indicated for the prevention of
stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation. While no …
stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation. While no …
[HTML][HTML] Once-or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: a meta-analysis of randomized controlled trials
Background/Purpose Non-vitamin K antagonist oral anticoagulants (NOACs) have a half-life
of around 12 h. We aimed to clarify if there was any effect modification by dosing (once-or …
of around 12 h. We aimed to clarify if there was any effect modification by dosing (once-or …
Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial …
EM Gieling, HA van den Ham… - British journal of …, 2017 - Wiley Online Library
Aims Nonvitamin K antagonist oral anticoagulants (NOACs) are now available for the
prevention of stroke in patients with atrial fibrillation (AF) as an alternative to vitamin K …
prevention of stroke in patients with atrial fibrillation (AF) as an alternative to vitamin K …
[HTML][HTML] Real-world oral anticoagulants for Asian patients with non-valvular atrial fibrillation: a PRISMA-compliant article
SM Kim, ET Jeon, JM Jung, JS Lee - Medicine, 2021 - journals.lww.com
Background and Purpose: This study aimed to evaluate the comparative efficacy and safety
of 4 non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in Asians with non …
of 4 non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in Asians with non …
[HTML][HTML] Management and outcomes of real-world use of non-vitamin-K oral anticoagulants (NOACs) in patients with atrial fibrillation: experience of a dedicated NOAC …
A De Veer, N Bennaghmouch, M Wijffels… - Netherlands Heart …, 2019 - Springer
Background Current guidelines recommend non-vitamin‑K oral anticoagulants (NOACs) as
the first-choice therapy for stroke prevention in patients with atrial fibrillation (AF). The use of …
the first-choice therapy for stroke prevention in patients with atrial fibrillation (AF). The use of …
The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized …
TA Zelniker, CT Ruff, EM Antman… - … Heart Journal: Acute …, 2019 - academic.oup.com
Background Patients with atrial fibrillation and concomitant coronary artery disease (CAD)
are at higher risk for myocardial infarction or cardiovascular death, often require antiplatelet …
are at higher risk for myocardial infarction or cardiovascular death, often require antiplatelet …
Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis
M Grymonprez, C Simoens, S Steurbaut… - EP …, 2022 - academic.oup.com
Aims Non-vitamin K antagonist oral anticoagulants (NOACs) are effective and safe
alternatives compared with vitamin K antagonists (VKAs) for thromboembolic prevention in …
alternatives compared with vitamin K antagonists (VKAs) for thromboembolic prevention in …
Association of ischemic stroke, major bleeding, and other adverse events with Warfarin Use vs Non–vitamin K antagonist oral anticoagulant use in patients with atrial …
CT Tsai, JN Liao, CE Chiang, YJ Lin… - JAMA network …, 2020 - jamanetwork.com
Importance Current guidelines recommend the use of non–vitamin K antagonist oral
anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation (AF). Data …
anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation (AF). Data …
Comparative efficacy and safety of the non–vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation
K Senoo, GYH Lip - Seminars in Thrombosis and Hemostasis, 2015 - thieme-connect.com
The non–vitamin K antagonist oral anticoagulants (NOACs), such as the thrombin inhibitor
(dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have …
(dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have …